PMID- 15125885
OWN - NLM
STAT- MEDLINE
DCOM- 20041223
LR  - 20131121
IS  - 1096-6374 (Print)
IS  - 1096-6374 (Linking)
VI  - 14
IP  - 3
DP  - 2004 Jun
TI  - The insulin-like growth axis in patients with autoimmune thyrotoxicosis: effect 
      of antithyroid drug treatment.
PG  - 235-44
AB  - OBJECTIVE: Hyperthyroidism is associated with altered growth hormone (GH) 
      secretion. Many patients with thyroid dysfunction experience several poorly 
      described complications such as symptoms and signs also seen in patients with 
      growth hormone deficiency (GHD). We have therefore prospectively evaluated a 
      possible relationship between the thyroid function, body composition, leptin 
      levels and insulin-like growth factor (IGF) related peptides in patients with 
      Graves' disease. DESIGN, PATIENTS, AND MEASUREMENTS: In a prospective group of 24 
      fasting female patients with Graves' disease (mean age (CI 95%): 40 years 
      (33-47)), we measured serum thyroxine, triiodothyronine, thyrotropine (TSH), TSH 
      receptor antibodies, anti-thyroid peroxidase, leptin, body composition, body mass 
      index (BMI) and IGF-related peptides at diagnosis and after 12 months of 
      treatment with thiamazol (ATD). RESULTS: In thyrotoxic patients IGF-I plus IGF-II 
      correlated positively with IGFBP-3 at baseline (r = 0.90, p < 0.1 x 10(16)) and 
      after 12 months follow-up (r = 0.87, p < 0.1 x 10(-16)). In the thyrotoxic state 
      total IGF-I, IGF-II, IGF binding protein 3 (IGFBP-3) and acid-labile subunit 
      (ALS) but not free IGF-I decreased significantly from 223 microg/L (189-260) 
      (mean (CI 95%), 877 microg/L (801-953), 4165 microg/L (3772-4577) and 22 mg/L 
      (18-26)) to 198 microg/L (172-226), 788 microg/L (711-865), 3431 microg/L 
      (3135-3741) and 19 mg/L (16-26) (p <0.006), respectively, after 12 months of ATD 
      despite an increase in BMI from 22 (21-23) to 23 kg/m(2) (22-25) (p < 0.0004) but 
      no significant changes in leptin. CONCLUSIONS: The complex IGF systems seemed 
      intact in thyrotoxic patients but change in body composition and the regulation 
      of leptin and insulin secretion during treatment of autoimmune thyroid disease 
      influence IGF-related peptides leaving the patient in a state somewhat similar to 
      partial GHD, but the mechanism behind these alterations remains unclear.
FAU - Zimmermann-Belsing, T
AU  - Zimmermann-Belsing T
AD  - Department of Endocrinology, PE-2131, University Hospital, Rigshospitalet, 
      Blegdamsvej 9, Copenhagen DK-2100, Denmark. tzb@dadlnet.dk
FAU - Juul, A
AU  - Juul A
FAU - Juul Holst, J
AU  - Juul Holst J
FAU - Feldt-Rasmussen, U
AU  - Feldt-Rasmussen U
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Growth Horm IGF Res
JT  - Growth hormone & IGF research : official journal of the Growth Hormone Research 
      Society and the International IGF Research Society
JID - 9814320
RN  - 0 (Immunoglobulins, Thyroid-Stimulating)
RN  - 0 (Insulin)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 0 (Leptin)
RN  - 0 (Somatomedins)
RN  - 0 (Thyroid Hormones)
RN  - 554Z48XN5E (Methimazole)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 67763-97-7 (Insulin-Like Growth Factor II)
RN  - EC 1.11.1.8 (Iodide Peroxidase)
SB  - IM
MH  - Adult
MH  - Body Composition
MH  - Female
MH  - Graves Disease/*drug therapy/metabolism
MH  - Humans
MH  - Immunoglobulins, Thyroid-Stimulating/blood
MH  - Insulin/blood/metabolism
MH  - Insulin-Like Growth Factor Binding Protein 3/blood/metabolism
MH  - Insulin-Like Growth Factor I/analysis/metabolism
MH  - Insulin-Like Growth Factor II/analysis/metabolism
MH  - Iodide Peroxidase/blood/metabolism
MH  - Leptin/blood/metabolism
MH  - Male
MH  - Methimazole/therapeutic use
MH  - Middle Aged
MH  - Somatomedins/*analysis
MH  - Thyroid Hormones/blood/metabolism
MH  - Thyrotoxicosis/*drug therapy/metabolism
EDAT- 2004/05/06 05:00
MHDA- 2004/12/24 09:00
CRDT- 2004/05/06 05:00
PHST- 2003/09/11 00:00 [received]
PHST- 2003/12/31 00:00 [revised]
PHST- 2003/12/31 00:00 [accepted]
PHST- 2004/05/06 05:00 [pubmed]
PHST- 2004/12/24 09:00 [medline]
PHST- 2004/05/06 05:00 [entrez]
AID - S1096637404000085 [pii]
AID - 10.1016/j.ghir.2003.12.015 [doi]
PST - ppublish
SO  - Growth Horm IGF Res. 2004 Jun;14(3):235-44. doi: 10.1016/j.ghir.2003.12.015.